Exozymes annual ebitda
2022
2023
2024
2025
Exozymes EBITDA Growth & History (EXOZ)
Exozymes's calculated EBITDA was −$9.4M for fiscal 2025.
View full Exozymes company overviewExozymes annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$9.4M | −$3.7M | — |
| 2024 | 2024-12-31 | −$5.7M | −$4.1M | — |
| 2023 | 2023-12-31 | −$1.6M | −$414,369 | — |
| 2022 | 2022-12-31 | −$1.2M | — | — |
Exozymes quarterly ebitda
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$2.9M | −$389,786 | — |
| Q1 2026 | 2026-03-31 | −$2.3M | −$418,636 | — |
| Q4 2025 | 2025-12-31 | −$2.6M | −$688,789 | — |
| Q3 2025 | 2025-09-30 | −$2.4M | −$897,400 | — |
| Q2 2025 | 2025-06-30 | −$2.5M | −$1.2M | — |
| Q1 2025 | 2025-03-31 | −$1.9M | −$934,559 | — |
| Q4 2024 | 2024-12-31 | −$1.9M | — | — |
| Q3 2024 | 2024-09-30 | −$1.5M | −$1.2M | — |
| Q2 2024 | 2024-06-30 | −$1.3M | — | — |
| Q1 2024 | 2024-03-31 | −$945,666 | — | — |
| Q3 2023 | 2023-09-30 | −$342,124 | — | — |
Exozymes ebitda trends
Between the periods ended 2022-12-31 and 2025-12-31, Exozymes's ebitda decreased from −$1.2M to −$9.4M, a change of −$8.2M. The latest reported quarter, Q2 2026, shows −$2.9M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Exozymes source filings ↗Community posts
eXoZymes selects Curia to scale up its NCT manufacturing process
eXoZymes ($EXOZ) entered an agreement with contract manufacturer Curia to transfer and scale its NCT production process. Work will take place at Curia facilities in Spain and Italy, covering enzyme production, the cell-free reaction and pro ...